USPTO Examiner THOMAS TIMOTHY P - Art Unit 1614

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19058112USE OF EFFECTIVE PART EXTRACT OF MONOCHASMA SAVATIERI IN PREPARATION OF DRUG FOR TREATING INFLAMMATORY DISEASE OR TUMORMarch 2025January 2026Abandon1101NoNo
19075007METHODS OF TREATING MIGRAINES WITH A COMBINATION OF A MELOXICAM AND A RIZATRIPTANMarch 2025November 2025Allow811YesNo
19056358CHEMICAL STRUCTURES THAT CONTROL METABOLIC ELIMINATION OF AMINOSTEROLSFebruary 2025October 2025Allow811YesNo
18587175ORAL GLIPTIN COMPOSITIONS AND METHOD FOR PREPARATION THEREOFFebruary 2024January 2025Allow1111NoNo
18443875HYDROCORTISONE ORAL LIQUID FORMULATIONSFebruary 2024December 2024Abandon1001NoNo
18411219TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORMJanuary 2024February 2026Abandon2501NoNo
18541291SUPRAMOLECULAR BIOMEDICAL POLYMERSDecember 2023December 2025Allow2420YesNo
18493090QUATERNARY AMMONIUM CYCLODEXTRIN AND PREPARATION METHOD AND USES THEREOF, AND SILVER NANOPARTICLE-CYCLODEXTRIN COMPLEX AND PREPARATION METHOD AND USES THEREOFOctober 2023December 2024Allow1421NoNo
18556634PURIFIED PSYCHOACTIVE ALKALOID EXTRACTION USING ACIDIFIED ACETONEOctober 2023May 2025Abandon1811NoNo
18481549FORMULATIONS OF DAZUCORILANT, A GLUCOCORTICOID RECEPTOR MODULATOROctober 2023March 2025Allow1721YesNo
18465893BUPIVACAINE LIQUID FORMULATIONSSeptember 2023February 2026Allow2931YesNo
18239072COMPOSITIONS AND METHODS FOR THE TREATMENT OF PRESBYOPIAAugust 2023October 2024Abandon1420NoNo
18340702COMPOSITIONS AND METHODS FOR TOPICAL TREATMENT OF VASCULAR CONDITIONSJune 2023January 2025Abandon1931YesYes
18335052METHODS OF TREATMENTJune 2023March 2026Abandon3321NoNo
18324305INJECTABLE PHARMACEUTICAL COMPOSITIONS COMPRISING A CYCLODEXTRIN, A HYDROPHOBIC DRUG, A CO-SOLVENT AND A PRESERVATIVEMay 2023February 2026Allow3311NoNo
183225211,4-DISUBSTITUTED PYRIDAZINE QUINOLNE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONSMay 2023October 2025Abandon2901NoNo
18310575SOLUTIONS FOR ORAL DOSAGEMay 2023January 2025Allow2021YesNo
18132144CONTACT LENS PRODUCT HAVING ANTIOXIDATIVE FUNCTIONApril 2023October 2025Abandon3021NoNo
18128550COMPOSITIONS AND KITS FOR OMEPRAZOLE SUSPENSIONMarch 2023July 2025Allow2841YesNo
18026765SPECIALIZED PRO-RESOLVING MEDIATORS (SPMs) AS MELANOCYTE GROWTH PROMOTER AND PRO-SURVIVAL FACTORS AND USES THEREOFMarch 2023September 2024Allow1821NoNo
18184135METHODS OF ADMINISTERING AN ARIPIPRAZOLE INJECTABLE PREPARATIONMarch 2023December 2024Abandon2141YesNo
18177694POLY(ETHYLENE GLYCOL)-BLOCK-POLY(PROPYLENE SULFIDE) NANOCARRIER PLATFORM FOR ENHANCED EFFICACY OF IMMUNOSUPPRESSIVE AGENTSMarch 2023January 2026Abandon3521NoNo
18115690CRILA® AND EGCG COMPOSITIONS FOR TREATMENT OF FIBROIDSFebruary 2023June 2025Allow2741YesNo
18075720COMPOSITIONS AND METHODS FOR THE TREATMENT OF PRESBYOPIADecember 2022December 2024Abandon2401NoNo
17963502METHODS OF TREATING AND/OR PREVENTING ACTINIC KERATOSISOctober 2022January 2026Allow4010NoNo
17995079TREATMENTSeptember 2022December 2025Abandon3801NoNo
17914163TREATMENT OF RESPIRATORY DISORDERSSeptember 2022November 2025Abandon3801NoNo
17939569COSMETIC COMPOSITION FOR PEEL-OFF-TYPE PACKS, AND METHOD FOR PRODUCING SAMESeptember 2022March 2025Allow3011YesNo
17903026USE OF EFFECTIVE PART EXTRACT OF MONOCHASMA SAVATIERI IN PREPARATION OF DRUG FOR TREATING INFLAMMATORY DISEASE OR TUMORSeptember 2022November 2024Allow2611YesNo
17895809ANTI-CANCER EFFECTS OF JAK2 INHIBITORS IN COMBINATION WITH THALIDOMIDE DERIVATIVES AND GLUCOCORTICOIDSAugust 2022May 2025Abandon3321NoNo
17894265PHOTOSENSITISING COMPOSITION AND USES THEREOFAugust 2022November 2024Abandon2711NoNo
17892782PHOSPHOLIPID COMPOSITIONSAugust 2022November 2024Allow2711NoNo
17889304Milrinone Composition and Method for Administering SameAugust 2022February 2025Abandon3011NoNo
17872921FORMULATIONS OF BRINCIDOFOVIRJuly 2022August 2025Allow3631YesYes
17851871IONIC LIQUIDS FOR INTERNAL DELIVERYJune 2022October 2025Abandon4021NoNo
1784303119-NOR C3,3-DISUBSTITUTED C21-N-PYRAZOLYL STEROID AND METHODS OF USE THEREOFJune 2022December 2024Abandon3011NoNo
17667909MULTI-KINASE INHIBITORS OF VEGF AND TGF BETA AND USES THEREOFFebruary 2022January 2026Abandon4711NoNo
17589012METHODS OF TREATING SARIN EXPOSURE WITH TETRAHYDROCANNABINOL AND CANNABIDIOL COMBINATIONSJanuary 2022May 2024Allow2811YesNo
17618152USING PARASYMPATHOMIMETIC DRUGS ALONE OR, IN COMBINATION WITH ONE OR MORE ALPHA AGONISTS IN PSEUDOPHAKIC PATIENTS, TO CREATE MULTI-FOCALITYDecember 2021May 2025Abandon4211NoNo
17540563TOLL LIKE RECEPTOR MODULATOR COMPOUNDSDecember 2021April 2025Allow4022YesNo
17527025HYALURONIC ACID-BASED GELS INCLUDING LIDOCAINENovember 2021September 2025Abandon4611NoNo
17493761SEED CONGLOMERATION: A DISRUPTIVE INNOVATION TO REDUCE CLEANING REQUIREMENTS OF SMALL SEEDED SPECIESOctober 2021March 2026Abandon5312NoNo
17602424METHODS AND COMPOSITIONS FOR USE IN TREATMENT OF CANCER WITHOUT PSYCHOACTIVE EFFECTSOctober 2021June 2025Abandon4401NoNo
17594292METHODS OF ADMINISTERING AN ARIPIPRAZOLE INJECTABLE PREPARATIONOctober 2021February 2025Abandon4011NoNo
17439136Macromolecule-Supported TLR AgonistsSeptember 2021May 2025Abandon4401NoNo
17437160NOVEL SALTS, CRYSTALLINE FORMS AND PREMIX OF HYPOLIPIDEMIC AGENTSeptember 2021November 2025Abandon5011NoNo
17467795METHODS AND COMPOSITIONS FOR REDUCING ALCOHOL TOXICITYSeptember 2021November 2024Abandon3821YesNo
17463258COMPOSITIONS AND KITS FOR OMEPRAZOLE SUSPENSIONAugust 2021March 2025Allow4331NoNo
17403813Method of treating and/or preventing viral infectionsAugust 2021September 2025Abandon4911YesNo
17310432AROMATIC RING OR HETEROAROMATIC RING COMPOUNDS, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOFAugust 2021April 2025Abandon4401NoNo
17426882SOLID FORMS OF A PROMOTER OF SPINOGENESISJuly 2021August 2025Allow4821NoNo
17426896IMIDAZOPYRIDINE DERIVATIVE COMPOUNDS AND USE OF SAMEJuly 2021August 2025Allow4911YesNo
17426281DISULPHIDE COMPOUNDSJuly 2021October 2024Abandon3901NoNo
17426411ABRASION-RESISTANT OPIOID FORMULATIONS WHICH RESIST ABUSE AND INCLUDE A SEQUESTERED OPIOID ANTAGONISTJuly 2021December 2024Abandon4101NoNo
17422397COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITYJuly 2021October 2025Abandon5121NoNo
17371585PHARMACEUTICAL USEJuly 2021October 2024Abandon3910NoNo
17311684METHODS, COMPOSITIONS AND KITS FOR TREATING MULTIPLE SCLEROSIS AND OTHER DISORDERSJune 2021January 2026Allow5631NoNo
17299928SYNERGISTIC COMPOSITIONS COMPRISING (R)-2-(2-OXOPYRROLIDIN-1-YL)BUTANAMIDE AND (S)-2-(2-e OXOPYRROLEDIN-1-YL)BUTANAMEDE IN A NON-RACEMIC RATIOJune 2021October 2025Abandon5231NoNo
17314746COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR, CEREBROVASCULAR AND OTHER VASCULAR DISEASE PATIENTSMay 2021November 2025Abandon5461NoNo
17283854COMPOSITIONS AND METHODS FOR CONTROLLING PLANT PESTS AND IMPROVING PLANT HEALTHApril 2021August 2025Abandon5202NoNo
17279536ALPHA-2C ADRENOCEPTOR ANTAGONISTS FOR THE TREATMENT OF SLEEP RELATED BREATHING DISORDERSMarch 2021November 2025Abandon5641NoNo
17267938MULTI-KINASE INHIBITORS OF VEGF AND TGF BETA AND USES THEREOFFebruary 2021August 2025Allow5461YesNo
17255887COMPOSITIONS COMPRISING AMINO ACIDS FOR USE IN THE PREVENTION AND TREATMENT OF LIVER DISEASESDecember 2020November 2024Allow4720NoNo
17252549STABILIZED HYALURONIC ACIDDecember 2020July 2025Allow5521NoNo
17120800SMALL MOLECULE MODULATORS OF PANTOTHENATE KINASESDecember 2020April 2025Abandon5211NoNo
17048803TOPOLOGICAL ADHESION OF MATERIALSOctober 2020September 2025Abandon5940YesNo
17072726USE OF ARTEMISININ FOR TREATING TUMORS INDUCED BY ONCOGENIC VIRUSES AND FOR TREATING VIRAL INFECTIONSOctober 2020July 2024Allow4521YesNo
17047155NECROPTOSIS INDUCERS OR AUTOPHAGY INHIBITORS OR A COMBINATION THEREOFOctober 2020March 2025Allow5321NoNo
16971280OSTEOCLAST DIFFERENTIATION INHIBITOR CONTAINING UROLITHINAugust 2020November 2025Abandon6041YesNo
16963219OPHTHALMIC COMPOSITIONS COMPRISING BILASTINE, A BETA-CYCLODEXTRIN AND AT LEAST ONE GELLING AGENTJuly 2020October 2025Abandon6041YesNo
16932111DERMAL PATCHES AND GLASS SWABS FOR APPLICATION OF TOPICAL IMMUNOSENSITIZERSJuly 2020December 2022Abandon2951YesYes
16955221SILICONE RESIN-COVERED SILICONE ELASTOMER PARTICLES, ORGANIC RESIN ADDITIVE, AND OTHER USESJune 2020September 2024Allow5131YesNo
16893903PHARMACEUTICAL FORMULATION FOR THE ELIMINATION OF CAUSATIVE AGENTS OF HERPESVIRAL INFECTIONS FROM THE TISSUES OF A MACROORGANISMJune 2020November 2024Abandon5441NoNo
16891391POLY(ETHYLENE GLYCOL)-BLOCK-POLY (PROPYLENE SULFIDE) NANOCARRIER PLATFORM FOR ENHANCED EFFICACY OF IMMUNOSUPPRESSIVE AGENTSJune 2020October 2025Abandon6051NoNo
16879075Telomerase Reverse Transcriptase (TERT) Expression Enhancing Compounds and Methods for Using the SameMay 2020December 2024Allow5571YesNo
15931270COMPOSITIONS AND METHODS FOR TREATING KERATINOUS SUBSTRATESMay 2020March 2025Allow5822YesNo
16761779EXTENDED RELEASE FORMULATIONS FOR INTRA-ARTICULAR APPLICATIONSMay 2020April 2025Allow6051NoNo
16649268Ophthalmic Pharmaceutical Composition, Ophthalmic Kit, and Pharmaceutical Application ThereofMarch 2020August 2024Allow5351YesNo
16645975METHODS OF TREATING EPILEPSY OR STATUS EPILEPTICUSMarch 2020October 2024Abandon5541NoNo
16642620Methods Of Enhancing And/Or Stabilizing Cardiac Function In Patients With Fabry DiseaseFebruary 2020July 2025Abandon6031NoYes
16624439Method of Treatment of CancerDecember 2019May 2025Abandon6061NoNo
16713460BENEFIT AGENT CONTAINING DELIVERY PARTICLEDecember 2019September 2025Abandon6061NoNo
16618779LOW-ALCOHOL ANTIMICROBIAL COMPOSITION AND USE THEREOFDecember 2019January 2025Abandon6041NoYes
16486290FORMULATIONS OF CANNABINOIDS FOR THE TREATMENT OF DERMATITIS AND INFLAMMATORY SKIN DISEASESAugust 2019November 2025Abandon6041NoYes
16451999METHODS OF TREATING SKIN WITH AROMATIC SKIN-ACTIVE INGREDIENTSJune 2019December 2024Allow6031YesYes
16425580ANTIMICROBIAL COMPOSITIONSMay 2019July 2024Allow6020YesYes
16224433INJECTABLE PHARMACEUTICAL COMPOSITIONS COMPRISING A CYCLODEXTRIN A HYDROPHOBIC DRUG, A CO-SOLVENT, AND A PRESERVATIVEDecember 2018April 2025Allow6041NoYes
16210714Extruded Immediate Release Abuse Deterrent PillDecember 2018March 2020Allow1511YesNo
16084207Food Compositions for WeaningSeptember 2018December 2025Abandon6080NoYes
16081290GLYCOALKALOID COMBINATIONS AND VARIOUS USES THEREOFAugust 2018March 2025Allow6041YesNo
15780320A METHOD FOR PREPARATION OF REDUCIBLE DEGRADABLE HYPERBRANCHED POLYMERIC MICELLESMay 2018January 2020Allow1910NoNo
15960004PHARMACEUTICAL FORMULATIONS OF NITRITE AND USES THEREOFApril 2018November 2021Abandon4221YesYes
15728196COMPOSITIONS, METHODS OF MAKING A COMPOSITION, AND METHODS OF USEOctober 2017August 2025Abandon6081YesNo
15538828NANOPARTICLES AND THEIR USE IN CANCER THERAPYJune 2017March 2020Allow3232YesNo
15505897METHODS AND REAGENTS FOR PREVENTION AND/OR TREATMENT OF INFECTIONFebruary 2017January 2026Abandon60110YesYes
15332805Cyclic Peptidomimetic Compounds as ImmunomodulatorsOctober 2016February 2018Allow1601YesNo
152286744-PREGENEN-11BETA-17-21-TRIOL-3,20-DIONE DERIVATIVESAugust 2016July 2019Allow3521NoNo
15115479OIL-IN -WATER EMULSION SUNSCREEN COMPOSITIONJuly 2016October 2024Allow60100NoYes
14386160COMPOSITIONS AND METHODS FOR REGULATING HAIR GROWTHSeptember 2014September 2025Abandon60131NoYes
14457714EXTRUDED IMMEDIATE RELEASE ABUSE DETERRENT PILLAugust 2014November 2018Allow51101YesYes

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner THOMAS, TIMOTHY P.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
10
Examiner Affirmed
6
(60.0%)
Examiner Reversed
4
(40.0%)
Reversal Percentile
60.8%
Higher than average

What This Means

With a 40.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
28
Allowed After Appeal Filing
5
(17.9%)
Not Allowed After Appeal Filing
23
(82.1%)
Filing Benefit Percentile
21.6%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 17.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner THOMAS, TIMOTHY P - Prosecution Strategy Guide

Executive Summary

Examiner THOMAS, TIMOTHY P works in Art Unit 1614 and has examined 187 patent applications in our dataset. With an allowance rate of 20.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 45 months.

Allowance Patterns

Examiner THOMAS, TIMOTHY P's allowance rate of 20.9% places them in the 2% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by THOMAS, TIMOTHY P receive 2.14 office actions before reaching final disposition. This places the examiner in the 58% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by THOMAS, TIMOTHY P is 45 months. This places the examiner in the 12% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +44.8% benefit to allowance rate for applications examined by THOMAS, TIMOTHY P. This interview benefit is in the 90% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 11.6% of applications are subsequently allowed. This success rate is in the 6% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 11.3% of cases where such amendments are filed. This entry rate is in the 11% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 0% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 47.4% of appeals filed. This is in the 13% percentile among all examiners. Of these withdrawals, 33.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.

Petition Practice

When applicants file petitions regarding this examiner's actions, 100.0% are granted (fully or in part). This grant rate is in the 89% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 3.2% of allowed cases (in the 80% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 5.1% of allowed cases (in the 81% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.